Quick Answer
Immuneering Corp reported Operating Income Loss of -$59.38 million for the year ending 2025.
- Immuneering Corp showed an increase of +7.3% in Operating Income Loss from 2024 to 2025.
- This data is from Immuneering Corp's annual report (Form 10-K), filed with the SEC on March 6, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Immuneering Corp's Operating Income Loss has declined by 247.6%.
- Historical annual values: Fiscal year 2025: -$59.38 million | Fiscal year 2024: -$64.07 million | Fiscal year 2023: -$58.41 million | Fiscal year 2022: -$51.74 million | Fiscal year 2021: -$33.89 million | Fiscal year 2020: -$17.08 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: